Pfizer, Bayer-backed Pyxis ups IPO price as biotech's public run continues unabated Samsung Biologics speeds $2B plant build forecast to boost capacity 70% Q3 2021's health tech funding blows previous years out of the water Caris Life Sciences, freshly past $1B VC funding mark, finds new finance head in ex-Medtronic SVP Amgen's latest Lumakras data in KRAS cancer underscore the bumpy road for combo strategy: analyst Takeda's transplant drug gets unanimous support of FDA AdComm despite concerns over diversity of its study ChemoCentryx scores first FDA approval in 24-year history, and CEO Schall sees a blockbuster in the making DreaMed Diabetes' 'digital endocrinologist' AI expands to Type 2 diabetes with FDA green light Schrödinger ropes MD Anderson into its development program for cancer inhibitors FDA stops all Allogene's CAR-T trials over safety scare, raising questions about future of gene editing Optum, SSM Health team up to tackle healthcare affordability, accessibility UCHealth stands firm on denying organ transplants to patients, donors who are unvaccinated for COVID-19 Featured Story | By Ben Adams As a barometer of the rude health biotechs continue to find themselves in on Wall Street, Big Pharma-backed oncology player Pyxis Oncology is upping its IPO. read more |
| |
|---|
|
Top Stories By Joseph Keenan Samsung Biologics is pushing for early completion of its new $2 billion manufacturing facility in an effort to meet increased demand and boost the South Korean CMO giant’s profits. read more By Dave Muoio Third quarter reports from Rock Health and StartUp Health place digital health funding at $6.7 billion and health innovation funding at $9.7 billion, respectively. Both groups also highlighted increases in fundraising deal size as well as merger and acquisition volume. read more By Andrea Park With great power comes great responsibility, and that’s surely the case for Caris Life Sciences’ new chief financial officer, who takes on the role as the sequencing startup enters an entirely new financial realm. read more By Angus Liu With Lumakras the first drug specifically approved for KRAS-mutated cancer, Amgen is examining various combination options to expand its reach. But new data underline the difficulty in finding the right partner. read more By Nick Paul Taylor Takeda’s faltering effort to deliver a wave of new products that will drive sales growth over the next decade has received a boost. Having seen its other prospects stumble in recent months, Takeda got back on track with unanimous FDA advisory committee votes in favor of a transplant drug. read more By Kevin Dunleavy ChemoCentryx has scored an FDA approval for Tavneos, an oral treatment for vasculitis, which leads to inflammation and destruction of small blood vessels. It is the first approval for ChemoCentryx in its 24-year history. The drug becomes the first approved in more than a decade for ANCA vasculitis. read more By Conor Hale It’s a common difficulty in many medical specialties: there typically aren’t enough specialists to go around. DreaMed Diabetes hopes to relieve some of the strain with its artificial-intelligence-powered system aimed not at patients but at clinicians. read more By Andrea Park The status of Schrödinger’s cat may be up in the air, but Schrödinger’s computational drug discovery platform is certainly still alive and kicking. read more By Nick Paul Taylor The FDA has sent shockwaves through the off-the-shelf CAR-T space, slapping a clinical hold on all of Allogene Therapeutics’ AlloCAR T clinical trials in response to an abnormality that could theoretically cause cancer. read more By Paige Minemyer Optum and health system giant SSM Health are joining forces to address the accessibility and affordability of healthcare. read more By Dave Muoio UCHealth took heat from a Colorado state legislator for its new policy requiring transplant patients and donors to be fully vaccinated. The system said that other transplant providers are implementing similar requirements. read more |
